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Abstract 
The blood-brain barrier (BBB) has a significant contribution to homeostasis and 
protection of the central nervous system (CNS). However, it also limits the 
crossing of therapeutics and thereby complicates the treatment of CNS 
disorders. To overcome this limitation, the use of nanocarriers for drug delivery 
across the BBB has recently been exploited. Nanocarriers can utilize different 
physiological mechanisms for drug delivery across the BBB and can be modified 
to achieve the desired kinetics and efficacy. Consequentially, several 
nanocarriers have been reported to act as functional nanomedicines in preclinical 
studies using animal models for human diseases. Given the rapid development 
of novel nanocarriers, this review provides a comprehensive insight into the most 
recent advancements made in nanocarrier-based drug delivery to the CNS, such 
as the development of multifunctional nanomedicines and theranostics. 
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Introduction 
Brain disorders, such as brain tumors (glioblastomas, neuroblastomas), 
neuropsychiatric disorders, or neurodegenerative disorders, are among the most 
difficult to treat diseases due to limited diagnostic and therapeutic options. In fact, 
the functional presence of the blood-brain barrier (BBB) and the blood-
cerebrospinal fluid (CSF) barrier restricts the transportation of drugs and imaging 
probes into the brain [1]. To overcome this limitation, many recent strategies 
have been explored, of which the use of multifunctional nanocarriers as drug-
delivery systems has emerged as one of the most promising [2]. 
 
Nanocarriers are structures whose selected size (with 50% or more of the 
particles in the size distribution having one or more external dimensions in the 
size range of 1 - 100 nm), optical, magnetic, photodynamic and other properties 
allow them to act as drug delivery systems. Especially the ability, after 
modification, to cross the BBB and even target specific sites within the brain has 
led to a steep increase in the use of nanotechnology in biomedical research on 
brain disorders. 
To be able to cross the BBB, nanocarriers such as nanoparticles (NPs) can be 
covalently linked to specific targeting agents, for example, exploiting vesicular 
trafficking mechanisms of brain capillary endothelial cells [3]. These ligands may 
also serve to direct the NPs to specific sites such as tumors (e.g., glioblastomas) 
[4] or protein aggregates (e.g., senile plaques in Alzheimer’s Diseases (AD)) [5].  
Different nanocarriers, dependent on the material, shape (mesoporous 
structures, particles), and ligands selected have different physicochemical and 
mechanical properties. This allows them to be tailored either for increased brain-
targeted delivery of diagnostic agents, therapeutic drugs, or both in the case of 
theranostic nanocarriers [6]. Although many nanocarriers, in particular 
theranostic nanocarriers, are still in the early translational stages, recent 
advances towards functional nanomedicines (NMeds) based on BBB crossing 
nanocarriers have been made. 
 
Classic and novel nanocarriers for drug delivery across the blood-brain 
barrier 
A wide range of nanocarriers have been designed and explored for drug delivery 
across the BBB, from altering shape and size for functionalization and utilization 
of the materials' thermal, optical, and biological properties. Among them, 
inorganic solid NPs, lipid-based liposomes, solid-lipid NPs, polymer-based NPs, 
and protein-based NPs were the most frequently used [7]. Furthermore, other 
material types such as dendrimers, nanoemulsions, nanosuspensions, and 
nanogels have been investigated for drug delivery into the brain. In recent years 
there has been a significant increase in the number of novel nanocarriers with 
unique compositions and properties [8] such as, but not limited to, nanomicelles, 
exosomes [9,10], metal-organic frameworks (MOFs) [11], zeolitic imidazolate 
framework-8 (ZIF-8) nanosheets with curcumin [12], graphene oxide in 
combination with naturally derived materials such as laminin (trees), kaolin nano 
clay [13] and laminarin (marine) [14], green nanomaterials such as zein protein 
[15], and finally, plant-based synthesis of metallic nanocarriers [16]. 
In particular, extracellular vesicles (EVs), lipid-bilayered nanoparticles released 
by most cell types in the body, are capable of inducing biological effects on target 
cells through the transfer of protein/nucleic acid species and the presentation of 
cell-targeting surface markers. EVs are further stratified into three categories 
based on size: apoptotic bodies (1 to 5 µm), shedding microvesicles (200 to 1000 
nm), and exosomes (30 to 200 nm) [10]. 
 
Ultimately, both classic and novel nanocarriers are designed to overcome the 
BBB toward drug delivery. Each material, shape, and design has to overcome 
cytotoxic effects and may be functionalized by ligand binding and conjugation. 
The burden of proof to demonstrate clinical impact now lies with each research 
group that proposes another ‘novel' nanocarrier [17]. Therefore, rather than 
increasing our list of nanocarriers, we should focus on the most effective and 
optimized nanocarrier for each application. 
An effort to standardize how we characterize all nanocarriers for traversal of the 
BBB is needed to improve the clinical efficacy of classic or novel nanocarriers. 
The controllable properties of nanocarriers make them ideal for biomedical 
applications but concurrently raise issues when trying to compare one 
nanocarrier to another, particularly when scaling from pre-clinical to clinical 
testing [18,19]. However, EVs may represent a potential breakthrough in targeted 
neurodegenerative disease treatment, as they inherently are cell targeting, 
protect their drug cargo, immune evasive, non-cytotoxic, and are easy to load 
[10]. 
 
Nanocarriers designed for the exploitation of specific cellular pathways for 
blood-brain barrier crossing, and improved blood-brain barrier crossing 
kinetics and efficacy  
The vast majority of the nanocarriers described above exploit existing 
physiological mechanisms to traverse the BBB. The BBB is a physical but 
dynamic biological barrier between the blood circulation and the CNS. Transport 
systems allow the passage of large “entities” across the endothelium and consist 
of a wide variety of pathways. Generally, as reported by [20-23], the intracellular 
transport of macromolecules is mediated by the vesicular system, and three 
types of endocytic vesicles are involved, namely, clathrin-coated pits involved in 
most of the receptor-mediated transcytosis, caveolae which are connected to 
adsorptive-mediated endocytosis of extracellular molecules and receptor 
trafficking, and macropinocytotic vesicles.  
Recent literature has highlighted the ability of EVs to cross the BBB via 
transcytosis [24,25]. The most comprehensive study to date used in vitro and in 
vivo models to demonstrate that tumor-derived EVs can breach the intact BBB 
via transcytosis [24]. The endothelial recycling endocytic pathway is identified as 
the transcellular transport mechanism with EVs circumventing the low 
transcytosis by decreasing brain endothelial expression of rab7 and therefore 
increasing transport efficiency [24]. 
It is estimated that clathrin-coated vesicles are involved in most of the 
internalization processes mediated by approximately 20 different receptors in 
brain endothelial cells. Amongst the receptors that could be considered for BBB 
crossing of nanocarriers are those, where endogenous substrates are easily 
recognized. In particular, Transferrin Receptor (TfR), Insulin Receptor (InsR), 
Leptin Receptor (LpR) or low-density lipoprotein (LDL) receptor-related protein 1 
(LRP-1) Receptors. These pathways help macromolecules in crossing the BBB 
and often have been exploited in the passage of nanocarriers to the CNS [26-28]. 
A major concern on these types of approaches is related to the possible 
saturation of the target receptors due to endogenous substrates. Thus, as an 
alternative strategy, exploitations of peptide-engineered nanocarriers with ligands 
able to stimulate endo-transcytosis at BBB level or non-competitive substrates of 
endothelial receptors were attempted in recent years. These approaches 
intended to create nanocarriers which are not involved in the “saturation” 
process, but rather exploit “saturable-free” transport mechanisms [29-33]. In 
general, the most common ligands are short peptides or antibodies linked to 
different nanocarriers (polymeric nanoparticles or liposomes).  
Focusing only on the most recent advances in ligand-based approaches, 
concerning LRP-1 receptor, dual-targeting drug delivery system involving 
Angiopep-2-conjugated biodegradable polymersomes loaded with doxorubicin 
were recently developed to exploit transport by the low-density lipoprotein 
receptor-related protein 1 (LRP1), which is overexpressed in both BBB and 
glioma cells [34]. In vivo experiments have shown that this approach leads to a 
more extensive distribution and more abundant accumulation in glioma cells and 
that the survival time of glioma-bearing rats treated with this nanomedicine was 
significantly prolonged. Similarly, a derivative of the same peptide (angiopep-2) 
was used to produce and test multifunctional Angiopep-2-modified nanoparticles, 
further targeted with IP10-EGFRvIIIscFv fusion protein able to recruit activated 
CD8+ T lymphocytes to glioblastoma cells [35]. Other in vivo experiments 
showed efficacy in tumor decrease and targeting. Regarding TfR, a plethora of 
experiments were conducted by using both antibodies, and ligand targeting 
approach, by using liposome, gold, or polymeric NPs or dendrimers [36-38]. 
Non-receptor mediated BBB crossing approach was also widely attempted, as 
previously stated with relevant in vivo outcomes in several pathological animal 
models, showing both CNS targeting and pathological phenotype rescues 
[39,40]. 
 
Recent advances in the use of BBB crossing nanocarriers in the 
development of NMeds for the treatment of brain disorders  
Few nanocarriers have been used in clinical studies so far. However, recently, 
promising nanocarriers have been engineered and characterized in basic 
research and preclinical studies that will inform the next generation of BBB 
crossing NMeds. Primarily, BBB crossing and targeting of brain tumors have 
been intensively pursued. 
Ideally, nanocarriers for the treatment and diagnosis of brain tumors such as 
glioblastomas should involve specific targeting and/or staining of the tumor cells 
for drug delivery or diagnosis and visual support during surgery to distinguish 
cancer cells from healthy tissue, which allows complete resection without 
damaging the nearby structures. BBB crossing can be mediated, and brain 
tumors can be specifically targeted through NP ligands such as CTX, CTX73, 
and anti-PDGFRβ [41,42]. Similarly, quantum dots (QDs) modified with tumor-
targeting ligands such as aptamer 32 could realize specific clinical imaging. 
These QDs were shown to accumulate in gliomas and produce measurable 
fluorescence [43]. Further, polyacrylamide NPs loaded with the dye methylene 
blue, coomassie blue, and indocyanine green have been modified at their surface 
using an F3 targeting peptide and cysteine [44] or F3 and PEG [45] to prevent 
non-specific binding. These NPs have been shown to stain gliosarcoma cells in 
vitro and allow tumor-visualization under normal light.  
Apart from visualization, targeted drug delivery has been achieved. For example,  
Doxorubicin and Paclitaxel, potent cytotoxic drugs that have low solubility and 
BBB crossing ability, have been loaded in NPs, which enhanced the delivery in 
tumors [46]. Further, increased targeting can be achieved by approaches 
integrating stimuli-responsive linkers into polymers used for NP generation. For 
example, oxidative stress is central to several brain diseases and increased in 
tumor tissue. Recently, the design of a polymer (mPEG) that responds to a ROS 
stimulus using a ROS-cleavable moiety (Thioketal) that links polymer and drug 
was reported [47], which will allow the more targeted release of drugs at sites of 
high oxidative stress. 
Yang et al. [48] loaded anti-cancer drugs into brain endothelial cell-derived 
exosomes and delivered them successfully to human glioblastoma astrocytoma 
cells in vitro and zebrafish brains in vivo, which decreased tumor growth. For a 
comprehensive overview of nanomedical approaches in the treatment of brain 
tumors see [49]. 
 
Neuropsychiatric disorders are especially difficult to treat, as there is often no 
clear pathology visible in the brain that allows for targeted drug delivery. In 
contrast, in neurodegenerative diseases such as Parkinson's disease and 
Alzheimer's disease (AD), specific pathological hallmarks are present in the 
brain, such as the aggregation of extracellular amyloid-beta (Aβ) in AD. Targeting 
the Aβ peptide during its various stages of aggregation using nanocarriers for 
diagnostic, therapeutic, and/or theranostic purposes is a major goal in NMed 
development [50]. For example, nanogels have been used as chaperons to 
inhibit Aβ fibril formulations [51], resulting in reduced Aβ cell toxicity in vitro [52]. 
In vivo, injection of zinc-loaded polymeric (PLGA) NPs with g7 ligand for BBB 
crossing was recently shown to reduce plaque size [40].  
Alvarez-Erviti et al. [53] engineered dendritic cell-derived exosomes to present 
with nervous system-specific protein (rabies viral glycoprotein) and contain 
siRNA which specifically targeted neurons, microglia, and oligodendrocytes in the 
brains of mice to achieve a knockdown of BACE1, a therapeutic target in 
Alzheimer’s disease. For a comprehensive overview of nanomedical approaches 
in the treatment of brain Alzheimer’s disease see [54]. 
 
Future perspectives  
 
Lessons from new models for the blood-brain barrier  
 
To improve our understanding of how nanocarriers respond following 
administration and their interaction with the BBB and CNS, medicine needs to 
reduce its reliance on costly and arduous in vivo models. However, this requires 
improved BBB mimetics to aid in our understanding of how nanocarriers are 
transported into the CNS and how therapeutic accumulation in the brain 
parenchyma can be achieved. Typically, traditional models of the BBB 
incorporated endothelial or epithelial cells, usually in a transwell system, to 
monitor nanocarrier permeability. That said, these models do not capture the true 
physiology of the sophisticated neurovascular unit resulting in an overestimation 
of nanocarrier delivery. 
Models have moved towards the incorporation of neural cells and basement 
membrane components to overcome this limitation. Co-culture models of the 
BBB, typically bi- or tri-cultures, include cells such as astrocytes, pericytes, 
microglia, fibroblasts, and/or neurons [55-62]. Incorporation of these cells can 
improve restrictive properties of the BBB model through the synergistic 
interactions leading to increased expression and organization of the tight 
junctions and, this, improved restrictive properties. Further improvements can be 
achieved by including ECM components such as collagens, laminins, fibronectin, 
nidogen, and/or heparan sulfate proteoglycans [63,64]. In addition to this, 
integrating dynamic flow through the use of microfluidic devices has also been 
found to stimulate improved barrier function in BBB cells. Numerous applications 
have found that imitating not only biochemical but also biomechanical ques leads 
to more realistic models through enhanced cellular organization and stimulation 
[65-68]. This, in turn, leads to a better understanding of pathophysiologies, and 
hence, improved treatment strategies. 
Finally, these models must be thoroughly explored not only in the context of 
restrictive properties, through classical methods such as transendothelial 
electrical resistance and tight junction expression, but also to confirm that all 
endothelial transporters are functioning correctly [65]. This includes examining 
the functionality of efflux pumps so as not to overestimate transport into the CNS 
[69]. The latter investigations are frequently overlooked when validating in vitro 
models, which could result in models that do not accurately depict active 
transport into and out of the brain, potentially omitting numerous routes for 
nanocarriers into the brain. 
 
Understanding the protein corona of nanocarriers  
 
Generally, the preferred route of administration of nanocarriers is the intravenous 
one. However, since in vivo experiments are often lacking, only a few studies on 
nanocarrier interaction with the circulatory components, and related to the 
absorption of plasma proteins, which generate a more or less stable corona 
around nanocarriers, are available. This “protein corona” (PC) generates a new 
surface of nanocarrier that provides new properties to them [70]. Quali- and 
quanti-tative composition of the PC can influence nanocarrier’s circulation, 
biodistribution, drug targeting, cellular uptake, and toxicity. For this reason, the 
study of the PC is now considered an urgent issue in the field of nanocarrier’s 
characterization, a requirement to better predict its biological identity features 
and to achieve the desired biological and therapeutic outcomes [71]. Several 
studies showed that there is no one “universal” plasma PC for all nanocarriers 
and that the relative densities of the adsorbed proteins do not generally correlate 
with their relative abundances in plasma. The composition of the PC is unique to 
each nanomaterial and depends on the synthetic identity of the nano-system. 
Walkey and Chan identified a subset of plasma proteins detected on at least one 
nanomaterial surface, and called it “adsorbome.” According to their results, in 
general, the plasma PC consists of 2-6 proteins adsorbed with high abundance 
and many others adsorbed with low abundance. In particular, they pointed out 
that the most abundant identified protein generally represents 29% of the total 
adsorbed proteins, while the top 3 most abundant proteins represent 56% of the 
total amount [72]. Therefore, a significant issue in the coming years, in order to 
get closer to on market authorization for nanocarriers, will be the identification of 
the PC connected to the different types of nanocarriers. To this end, physico-
chemical parameters of nanocarriers are important and need to be urgently 
investigated with this focus. In particular, the size of NPs strongly affects the 
formation of the PC, in terms of composition, conformation, rate of protein 
adsorption, and stability of PC. Even if general rules are impossible to clearly 
define, common knowledge is that bigger nanocarriers could deal with more 
extensive protein coverage. Smaller sizes typically increase corona thickness 
and decrease conformational change, and finally, substantial differences in size 
bring about differences in PC composition and protein relative abundance [73]. 
These considerations strongly impact on the process of production of 
nanocarriers that should be featured by the highest level of reproducibility. 
Connected to this aspect, also the shape of nanocarriers displays a great impact 
on the structure and composition of the PC. Not only the curvature effects differ 
from one nanocarrier’s shape to another, but also the coordination of the atoms 
on the available surfaces, leading to different surface energies for each different 
morphology, which might play a role in the protein binding [70,74]. 
Both the composition of nanocarrier (i.e., the material used as starting polymer) 
and the surface charge play an essential role in determining the protein adsorbed 
from the environment and the subsequent destiny of the nanocarrier [75]. This 
fact leads to balanced evaluation of the choice of the polymer to be used for 
nanocarrier production. In particular, it is known that hydrophilicity and 
hydrophobicity of the particle surface influence both the amount and identity of 
the proteins bound to the nanocarrier, as well as the exchange rates of bound 
proteins [76]. Also, hydrophobic nanocarriers are opsonized more quickly than 
hydrophilic NPs, due to the enhanced absorbability of plasma proteins onto the 
surface of hydrophobic particles [77]. 
All these aspects, which are typically considered ex-post, meaning after the 
nanocarriers production and only when required by regulatory entities, should be 
included in any nanocarrier design, and are of great importance for CNS drug 
delivery. A nanocarrier designed to cross the BBB after a systemic administration 
will be forced to be stable in the bloodstream until the transcytosis process is 
finished and without activating any “defense” mechanism. Therefore, 
nanocarriers should be carefully designed to avoid the formation of a PC that 
stimulates an immune response ab initio, instead of checking this at the end of 




Theranostics need to fulfill two critical criteria: they need to be efficiently targeted 
to the pathological site (e.g., tumor, plaque) and release a therapeutic drug in 
sufficient concentration. The modularity of nanocarriers makes them an ideal tool 
to reach both goals. Specific surface ligands allow them to cross the BBB and 
selectively target sites of interest, and incorporated imaging agents enable 
visualization of pathologic characteristics of a disease. At the same time, the 
encapsulation of drugs realizes the delivery of a therapeutic on demand. 
Besides, many NPs can be biodegraded into nontoxic byproducts, and thus 
considered to be relatively safe for humans. Both theranostic organic and 
inorganic NPs have been recently explored in predominantly experimental and 
preclinical studies, yet few satisfy all the criteria mentioned above so far [6]. 
These theranostic nanocarriers were based on existing NPs with proven imaging 
capabilities such as QDs, iron oxide NPs, and gold nanocages that were 
modified to deliver a conjugated or loaded therapeutic agent. Alternatively, 
incorporation, loading, or linking of fluorescent dyes to drug-delivering NPs such 
as liposomal and polymeric NPs was performed [78]. For example, indocyanine 
green (ICG, near-infrared (NIR) fluorescent probe) loaded liposomal NPs in 
conjugation with VEGF-bevacizumab were reported to enhance the visualization 
of brain tumors. [79].  
However, since the most commonly used methods for clinical imaging are MR 
(Magnetic Resonance), PET (Positron Emission Tomography), and SPECT 
(Single-Photon Emission Computed Tomography), a significant part of 
theranostic NP development is focusing on multimodal imaging to combine the 
effect of NPs and these traditional imaging technologies. For example, in a 
recent study, Angiopep-2 (ANG) was used as the ligand on PEGylated NPs to 
facilitate BBB crossing and tumor cell targeting [80]. Combined with 
upconversion luminescence (UCL), these nanocarriers could additionally function 
as MR/NIR-to-NIR UCL bimodal imaging agents [80]. 
Thus, encapsulating or conjugating both imaging and therapeutic agents together 
in biocompatible nanocarriers such as polymeric NPs, ferritin nanocages, and 
porous silica NPs and engineering of NPs with unique properties (e.g., tissue 
targeting, BBB crossing), and improving CNS delivery through the discovery of 
new ligands (e.g., Phage-derived shuttle peptides [81]) (Figure 1) will lead to 
advanced theranostic BBB drug-delivery NMeds [4] that further a precise 




Classic and novel nanocarriers for BBB crossing 
• Classic: inorganic solid NPs, lipid-based liposomes and solid-lipid NPs, polymer-based 
NPs, protein-based NPs, dendrimers, nanoemulsions, nanosuspensions, and nanogels. 
• Novel: nanomicelles, exosomes, metal-organic frameworks (MOFs), Zeolitic imidazolate 
framework-8 (ZIF-8) nanosheets, graphene oxide in combination with naturally derived 
materials, zein protein, extracellular vesicles (EVs). 
Nanocarriers designed for the exploitation of specific cellular pathways for BBB crossing  
• An effort of standardization of how we characterize all nanocarriers for traversal of the 
BBB is needed. 
• Nanocarriers exploit existing physiological mechanisms to traverse the BBB (the 
vesicular system): cross the BBB via transcytosis. 
• It is estimated that clathrin-coated vesicles are involved in most of the internalization 
processes mediated by receptors on endothelial cells. 
NMeds for the treatment of brain disorders  
• Nanocarriers have been mostly used in basic research and preclinical studies, primarily 
for targeting of brain tumors, and in AD. 
• Ideally, nanocarriers should enable specific targeting, visualization, and drug delivery. 
• Novel approaches integrate stimuli-responsive linkers into polymers (e.g., responding to 
oxidative stress). 
New models for the blood-brain barrier  
• Improved BBB mimetics to understand BBB crossing of nanocarriers move towards the 
incorporation of neural cells and basement membrane components. Co-culture models of 
the BBB include cells such as astrocytes, pericytes, microglia, fibroblasts and/or neurons, 
and ECM components. 
• Integrating dynamic flow through microfluidic devices has been found to stimulate 
improved barrier function. 
• BBB models must be thoroughly characterized regarding transendothelial electrical 
resistance, tight junction, and endothelial transporter expression and function 
The protein corona of nanocarriers  
• Plasma proteins generate a protein corona (PC) around nanocarriers, which is not well 
investigated so far. 
• The PC generates a new surface of nanocarrier, influencing circulation, biodistribution, 
drug targeting, cellular uptake, and toxicity.  
• The plasma PC consists of few proteins adsorbed with high abundance and many others 
adsorbed with low abundance. 
• The composition of nanocarrier and the surface charge play an essential role in 
determining the types of proteins adsorbed. 
• The careful design of nanocarriers needs to consider the PC. 
Theranostic nanocarriers  
• Theranostic nanocarriers need to efficiently target the pathological site, release a drug, 
and possess imaging capabilities. 
• Theranostic nanocarriers will lead to advanced BBB drug-delivery NMeds for precise 




Figure1: Overview of multifunctional BBB crossing nanocarriers. Nanocarriers may utilize 
endogenous BBB crossing pathways to achieve CNS targeting through modification with targeting 
ligands. Further, these ligands may realize specific targeting within the brain. In addition, 
nanocarriers of different types can be modified to have diagnostic potential, e.g., being detectable 
by various imaging techniques, and have therapeutic potential by drug encapsulation or 
conjugation. The selection of type, diagnostic approach, targeting strategy, and drug allows the 
creation of theranostic nanocarriers that will open so far untapped possibilities for the 
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